Efficacy of immunotherapy rechallenge in locoregionally advanced nasopharyngeal carcinoma after progression: A real-world analysis - PubMed
6 hours ago
- #real-world analysis
- #immunotherapy rechallenge
- #nasopharyngeal carcinoma
- Immunotherapy rechallenge as first-line treatment after progression in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) did not significantly improve survival overall in a real-world analysis.
- In patients with an immunotherapy-free interval exceeding 1 year, immunotherapy rechallenge was associated with a significantly better prognosis.
- The study analyzed 160 patients from 24,183 screened, comparing 117 who received immunotherapy rechallenge with 43 who did not after disease progression.
- Primary endpoint was progression-free survival after first relapse (PFS-r), with no significant advantage overall but notable benefit in specific subgroups.